Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F23%3A10464510" target="_blank" >RIV/00669806:_____/23:10464510 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00133352 RIV/00216208:11140/23:10464510 RIV/00216208:11150/23:10464510 RIV/65269705:_____/23:00078008 RIV/00179906:_____/23:10464510

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=E8ea-FyHA1" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=E8ea-FyHA1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2023/4653627" target="_blank" >10.1155/2023/4653627</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

Popis výsledku v původním jazyce

Background. The QuantiFERON (R)-Monitor (QFM) is an assay that measures interferon-gamma production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-gamma levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. Methods. This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-gamma was measured using the ELISA kit for the QFM and data were obtained in IU/ml. Results. The results showed that controls had nearly 2-fold higher levels of IFN-gamma (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. Conclusions. Results showed that controls had higher levels of IFN-gamma production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-gamma. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.

Název v anglickém jazyce

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

Popis výsledku anglicky

Background. The QuantiFERON (R)-Monitor (QFM) is an assay that measures interferon-gamma production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-gamma levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. Methods. This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-gamma was measured using the ELISA kit for the QFM and data were obtained in IU/ml. Results. The results showed that controls had nearly 2-fold higher levels of IFN-gamma (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. Conclusions. Results showed that controls had higher levels of IFN-gamma production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-gamma. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Immunology Research

ISSN

2314-8861

e-ISSN

2314-7156

Svazek periodika

2023

Číslo periodika v rámci svazku

April

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

4653627

Kód UT WoS článku

000970514700001

EID výsledku v databázi Scopus

2-s2.0-85152619602